Research is needed to help illustrate the size and nature of access gaps so that we can design better coverage policies. Ultimately, there is a need for policymakers to recognize that factors unrelated to whether an individual has a medical necessity for treatment can affect whether or not a person is likely to receive these medications, says study lead author Meghan Podolsky (SPH24), research fellow in the Department of Global Health and an SPH alum who completed the MS program in epidemiology last year
based in metro Atlanta
Some patients report feeling fuller more quickly during meals or experiencing reduced cravings for certain foods, particularly high-fat or sweet items
A 2025 trial found semaglutide resolved liver inflammation in a meaningful share of people with MASH
GLP-1 medications including Wegovy, Zepbound, and Foundayo carry a boxed warning regarding thyroid C-cell tumors based on animal studies
The Centers for Disease Control and Prevention (CDC) reports that more than 37 million Americans have diabetes, emphasizing the need for individualized therapies that improve glycemic control and long-term patient outcomes through precision-based drug interventions